Park West Asset Management’s Starling Oncology STLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-1,255,063
Closed -$12.5M 179
2021
Q2
$12.5M Hold
1,255,063
0.36% 68
2021
Q1
$12.5M Buy
1,255,063
+748,800
+148% +$7.98M 0.38% 69
2020
Q4
$5.47M Buy
506,263
+359,802
+246% +$3.7M 0.11% 98
2020
Q3
$1.52M Buy
+146,461
New +$1.52M 0.06% 87

Other funds holding STLN

Park West Asset Management's STLN Position: Q3 2021 in Review

Park West Asset Management sold out of Starling Oncology (STLN) in Q3 2021, closing a stake of 1,255,063 shares — an estimated $12.5M sold.

Park West Asset Management first reported a position in STLN in Q3 2020 and held it in 4 quarters. The position peaked at $12.5M in Q1 2021. 51 funds tracked by Wall St. Rank hold STLN as of Q3 2021.

  • Park West Asset Management reported no remaining Starling Oncology position as of Q3 2021 after selling out during the quarter.
  • Park West Asset Management sold 1,255,063 Starling Oncology shares in Q3 2021, an estimated $12.5M.
  • Park West Asset Management first reported a position in Starling Oncology in Q3 2020 and held it in 4 quarters.
  • Park West Asset Management's Starling Oncology position peaked at $12.5M in Q1 2021.
  • 51 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2021.

Based on Park West Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.